logo

For the Inventor, By the Inventor

Seoul, South Korea

Gi Innovation, Inc.


USPTO Granted Patents = 12


Forward Citations = 4

Loading Chart...
Loading Chart...

11 inventors (with patents filed for the assignee):

goldMedal Myung Ho Jang (8 out of 11 patents)

silverMedal Young Jun Koh (5 out of 14 patents)

bronzeMedal Su Youn Nam (4 out of 8 patents)

4.  Myoung Ho Jang (4 out of 7 patents)

5.  Zungyoon Yang (2 out of 4 patents)

6.  Young-Gyu Cho (2 out of 6 patents)

7.  Young Chul Sung (2 out of 25 patents)

8.  Heonchang Lim (1 out of 1 patent)

9.  Bo-Gie Yang (1 out of 1 patent)

10.  Kyungwha Lee (1 out of 1 patent)

11.  Dan Bee Ha (1 out of 1 patent)

12.  Young Min Oh (1 out of 1 patent)

13.  Soontak Kwon (0 patent)

14.  Young Min Oh (0 patent)


12 patents:

1. 12692307 - PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING AN IMMUNE CHECKPOINT INHIBITOR ANTIBODY AND A FUSION PROTEIN COMPRISING AN IL-2 MUTANT AND A CD80 EXTRACELLULAR DOMAIN (2026-07-28),
2. 12642764 - FUSION PROTEIN PREPARATION COMPRISING IL-2 AND CD80 PROTEINS (2026-06-02),
3. 12478675 - PHARMACEUTICAL COMPOSITION FOR ENHANCING RADIOTHERAPY COMPRISING FUSION PROTEIN CONTAINING IL-2 PROTEIN AND CD80 PROTEIN (2025-11-25),
4. 12414984 - Fusion protein comprising anti-CD73 antibody and IL-2, and use thereof (2025-09-16),
5. 12410233 - Extracellular domain of alpha subunit of IgE Fc receptor, pharmaceutical composition comprising same and method for producing same (2025-09-09),
6. 12409203 - Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of IGE FC receptor, and pharmaceutical composition comprising same (2025-09-09),
7. 12291555 - Fusion protein comprising IL-2 protein and CD80 protein, and use thereof (2025-05-06),
8. 12286464 - Fusion protein comprising IL-2 protein and CD80 protein, and use thereof (2025-04-29),
9. 12128076 - Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereof (2024-10-29),
10. 11857601 - Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug (2024-01-02),
11. 11639383 - Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain (2023-05-02),
12. 11492384 - Fusion protein comprising IL-2 protein and CD80 protein, and use thereof (2022-11-08),
Gi Innovation, Inc. is a technology-centric company focused on developing innovative solutions that enhance operational efficiency and streamline processes across various industries. With a commitment to research and development, Gi Innovation seeks to harness cutting-edge technology to solve complex challenges. The firm specializes in providing software and hardware solutions that are tailored to meet the specific needs of its clients. Driven by a team of experienced professionals, Gi Innovation aims to foster sustainable growth and innovation, ensuring that its products not only meet current market demands but also anticipate future trends. The company's approach is collaborative, working closely with stakeholders to deliver customized solutions that improve productivity and profitability.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

12 Patents

#342 in Seoul

#936 in South Korea

#48,055 in the World

Seoul, KR
Seoul, South Korea

Gi Innovation, Inc.

Forward Citations = 4

11 inventors:

goldMedal Myung Ho Jang (8 out of 11 patents)

silverMedal Young Jun Koh (5 out of 14 patents)

bronzeMedal Su Youn Nam (4 out of 8 patents)

4.  Myoung Ho Jang (4 out of 7 patents)

5.  Zungyoon Yang (2 out of 4 patents)

Please report any incorrect information to [email protected]
Loading…